Christine Micheel
Research Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
INTRODUCTION: Prostate cancer (PC) shows marked heterogeneity in clinical outcomes, from indolent to highly aggressive disease. Alterations in TP53, PTEN, RB1, and DNA damage repair genes are linked to poor patient outcomes, yet how the interaction and co-occurrence of these alterations impact prognosis remains unclear. We leveraged the AACR Project GENIE prostate cancer cohort to assess the prognostic impact of individual and concomitant gene alterations, focusing on key PC drivers (BRCA2, TP53, PTEN, RB1). METHODS: the study was conducted in two stages: (i) identification of candidate alterations at individual gene level through a systematic literature review, followed by analyzing the prevalence and co-occurrence of genes in the AACR Project GENIE Public Release (PR) dataset. (ii) Prognostic analysis of the pre-selected biomarkers in the AACR Project GENIE Biopharma Collaborative (BPC) cohort. Analyses were performed in three clinical settings (entire BPC cohort, n=1114; subgroup of patients with localized disease at diagnosis, n=837; and subgroup of patients with metastatic PC with a biopsy collected before or at the time of mPC, n=455) using two statistical approaches: univariate analysis (UA) and inverse probability weighting using propensity scores (PS). Cox models were applied to estimate overall survival hazard ratios (HRs). RESULTS: after integrating the findings from the systematic review with the analysis of the GENIE PR (n=5684), 107 individual genes and 122 co-occurring alterations were selected for study. In the GENIE BPC (n=1114 patients) 75% were M0 at diagnosis, and 67% presented metastatic PC at any time. Alteration prevalence was: TP53, 25%; PTEN, 15%; BRCA2, 4%; RB1, 4%; co-alterations included, PTEN-TP53 (6.4%), RB1-TP53 (2.1%), PTEN-RB1 (1.3%), and BRCA2-TP53 (1.2%). All four key genes showed a statistically significant prognostic impact in the entire cohort with UA (BRCA2, HR:1.9; TP53, HR:2.6; PTEN, HR:2.4; RB1, HR:4.1, all p<0.001). Results were consistent in the subgroup analysis and when using PS. Additional genes such as FANCA, PIK3CA, and MYC were also associated with poor outcomes. Among co-alterations, BRCA2-TP53 (HR:2.0, p=0.05), RB1-TP53 (HR:3.6, p<0.001), PTEN-TP53 (HR:2.4, p<0.001); PTEN-RB1 (HR:5.5, p<0.001), and PTEN-TP53-RB1 (HR:9.0, p<0.001) were the strongest predictors of poor survival, with consistent effects across subgroups and analytical methods. Other combinations including MYC-TP53 (HR 2.2, p<0.001) and PIK3CA-TP53 (HR 3.2, p<0.001), also showed independent prognostic value. CONCLUSIONS: Genomic alterations in TP53, PTEN, RB1, and BRCA2, alone and in combination, independently associate with poor prognosis. Co-alteration patterns such as PTEN-TP53-RB1 define aggressive molecular subsets. This evidence supports integrating genomic interaction patterns for enhancing clinical risk models and guiding precision patient management. Furthermore, this study highlights the potential of AACR Project GENIE to enable data-driven development of biomarker-informed patient care strategies. Citation Format: Pablo Cresta Morgado, Victor Navarro, Guillermo Vilacampa, Haitham Alatoom, Manuel Ramos del Rio, Irbaz Riaz, Shawn Sweeney, Nikolaus Schultz, Ken Kehl, Gregory Riely, Wasim Abida, Katherine Panageas, Deborah Schrag, Philippe Bedard, Christine Micheel, Xindi Guo, Chelsea Nayan, Rodrigo Dientsmann, Joaquin Mateo. Genomic prognostic biomarkers in prostate cancer from the AACR GENIE cohort [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Prostate Cancer Research and Treatment; 2026 Jan 20-22; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86(2_Suppl):Abstract nr A013.
Year:
2026
PURPOSE Primary barriers to application of immune checkpoint inhibitor (ICI) therapy for cancer include severe side effects (such as potentially life threatening pneumonitis [PN]), which can cause the discontinuation of treatment. Predicting which patients may develop PN while on ICI would improve both safety and potential efficacy because treatments could be safely administered for longer or discontinued before severe toxicity. METHODS Starting from a cohort of 3,351 patients with cancer who received previous ICI therapy at the Vanderbilt University Medical Center, we curated 2,700 contrast chest computed tomography (CT) volumes for 671 patients. Three different pure imaging models predicted the potential for PN using only a single time point before the first ICI dose. RESULTS The first model used 109 radiomics features only and achieved an AUC of 0.747 (CI, 0.705 to 0.789) with a positive predictive value (PPV) of 0.244 (CI, 0.211 to 0.276) at a sensitivity of 0.553 (CI, 0.485 to 0.621) using mainly features describing the global lung properties. The second model used a convolutional neural network (CNN) on the raw CTs to improve to an AUC of 0.819 (CI, 0.781 to 0.857) with a PPV of 0.244 (CI, 0.203 to 0.284) at a sensitivity of 0.743 (CI, 0.681 to 0.806). The third model combined both radiomics and deep learning but, with an AUC of 0.829 (CI, 0.797 to 0.862) and a PPV of 0.254 (CI, 0.228 to 0.281) at a sensitivity of 0.780 (CI, 0.721 to 0.840), did not show a significant improvement on the CNN-only model. CONCLUSION This new model suggests the utility of deep learning in PN prediction over traditional pure radiomics and promises better management for patients receiving ICI and the ability to better stratify patients in immunotherapy drug trials.
Year:
2025
Artificial intelligence chatbots have shown promise in medical settings, but their ability to interpret complex molecular data is not clear. Here, we assessed 50 different patient scenarios with clinical and molecular data and found that chatbots provided mostly accurate and comprehensive recommendations, although key treatment options were omitted occasionally, and non-data driven treatments were recommended in cases with multiple mutations.
Year:
2025
Year:
2025
Background While artificial intelligence (AI) has demonstrated potential in automating clinical trial matching, most existing solutions rely on high-level structured data or oversimplified criteria. This study introduces a framework to structure and analyze eligibility criteria across three real-world trial protocols, aiming to inform more granular AI-driven trial matching strategies. Methods Trial criteria from three protocols were decomposed into individual variables and evaluated based on data type, scope, and dependency. Complexity was assessed using a novel formula incorporating the number of independent and dependent variables, alongside the Flesch-Kincaid reading grade level. Quantitative analysis explored variation across trials. Results Protocols contained between 22–160 eligibility variables, with 4–22% showing interdependence. Reading grade levels ranged from sixth grade to first-year college. Complexity scores varied significantly, with some trials exhibiting particularly high cognitive and logical burdens. Recursive and hierarchical structures were prevalent in high-complexity protocols. Conclusion This study reveals the substantial variability and structural complexity of clinical trial criteria, highlighting challenges for AI matching systems. A standardized approach to measuring trial complexity can enhance algorithm transparency, scalability, and interpretability. These findings underscore the need for structured, computable frameworks to improve equity and efficiency in clinical trial recruitment.
Year:
2025
Purpose: We describe the clinical and genomic landscape of the non–small cell lung cancer (NSCLC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). Experimental Design: A total of 1,846 patients with NSCLC whose tumors were sequenced from 2014 to 2018 at four institutions participating in AACR GENIE were randomly chosen for curation using the PRISSMM data model. Progression-free survival (PFS) and overall survival (OS) were estimated for patients treated with standard therapies. Results: In this cohort, 44% of tumors harbored a targetable oncogenic alteration, with EGFR (20%), KRAS G12C (13%), and oncogenic fusions ( ALK, RET , and ROS1 ; 5%) as the most frequent. Median OS (mOS) on first-line platinum-based therapy without immunotherapy was 17.4 months [95% confidence interval (CI), 14.9–19.5 months]. For second-line therapies, mOS was 9.2 months (95% CI, 7.5–11.3 months) for immune checkpoint inhibitors (ICI) and 6.4 months (95% CI, 5.1–8.1 months) for docetaxel ± ramucirumab. In a subset of patients treated with ICI in the second-line or later setting, median RECIST PFS (2.5 months; 95% CI, 2.2–2.8) and median real-world PFS based on imaging reports (2.2 months; 95% CI, 1.7–2.6) were similar. In exploratory analysis of the impact of tumor mutational burden (TMB) on survival on ICI treatment in the second-line or higher setting, TMB z-score harmonized across gene panels was associated with improved OS (univariable HR, 0.85; P = 0.03; n = 247 patients). Conclusions: The GENIE BPC cohort provides comprehensive clinicogenomic data for patients with NSCLC, which can improve understanding of real-world patient outcomes.
Year:
2025
PURPOSE Although immune checkpoint inhibitors (ICIs) have improved outcomes in certain patients with cancer, they can also cause life-threatening immunotoxicities. Predicting immunotoxicity risks alongside response could provide a personalized risk-benefit profile, inform therapeutic decision making, and improve clinical trial cohort selection. We aimed to build a machine learning (ML) framework using routine electronic health record (EHR) data to predict hepatitis, colitis, pneumonitis, and 1-year overall survival. METHODS Real-world EHR data of more than 2,200 patients treated with ICI through December 31, 2018, were used to develop predictive models. Using a prediction time point of ICI initiation, a 1-year prediction time window was applied to create binary labels for the four outcomes for each patient. Feature engineering involved aggregating laboratory measurements over appropriate time windows (60-365 days). Patients were randomly partitioned into training (80%) and test (20%) sets. Random forest classifiers were developed using a rigorous model development framework. RESULTS The patient cohort had a median age of 63 years and was 61.8% male. Patients predominantly had melanoma (37.8%), lung cancer (27.3%), or genitourinary cancer (16.4%). They were treated with PD-1 (60.4%), PD-L1 (9.0%), and CTLA-4 (19.7%) ICIs. Our models demonstrate reasonably strong performance, with AUCs of 0.739, 0.729, 0.755, and 0.752 for the pneumonitis, hepatitis, colitis, and 1-year overall survival models, respectively. Each model relies on an outcome-specific feature set, though some features are shared among models. CONCLUSION To our knowledge, this is the first ML solution that assesses individual ICI risk-benefit profiles based predominantly on routine structured EHR data. As such, use of our ML solution will not require additional data collection or documentation in the clinic.
Year:
2024
Year:
2024
Year:
2024
PURPOSE Observational clinicogenomic data sets, consisting of tumor next-generation sequencing (NGS) data linked to clinical records, are commonly used for cancer research. However, in real-world practice, oncologists frequently request NGS in search of treatment options for progressive cancer. The extent and impact of this dynamic on analysis of clinicogenomic research data are not well understood. METHODS We analyzed clinicogenomic data for patients with non–small cell lung, colorectal, breast, prostate, pancreatic, or urothelial cancers in the American Association for Cancer Research Biopharmaceutical Consortium cohort. Associations between baseline and time-varying clinical characteristics and time from diagnosis to NGS were measured. To explore the impact of informative cohort entry on biomarker inference, statistical interactions between selected biomarkers and time to NGS with respect to overall survival were calculated. RESULTS Among 7,182 patients, time from diagnosis to NGS varied significantly by clinical factors, including cancer type, calendar year of sequencing, institution, and age and stage at diagnosis. NGS rates also varied significantly by dynamic clinical status variables; in an adjusted model, compared with patients with stable disease at any given time after diagnosis, patients with progressive disease by imaging or oncologist assessment had higher NGS rates (hazard ratio for NGS, 1.61 [95% CI, 1.45 to 1.78] and 2.32 [95% CI, 2.01 to 2.67], respectively). Statistical interactions between selected biomarkers and time to NGS with respect to survival, potentially indicating biased biomarker inference results, were explored. CONCLUSION To evaluate the appropriateness of a data set for a particular research question, it is crucial to measure associations between dynamic cancer status and the timing of NGS, as well as to evaluate interactions involving biomarkers of interest and NGS timing with respect to survival outcomes.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (9)
Jeremy L. Warner
Professor
Brown University
Neha Jain
Staff Scientist
Vanderbilt University Medical Center
Protiva Rahman
Research Assistant Professor
University of Florida
Kathleen F. Mittendorf
Research Assistant Professor of Medicine
Vanderbilt University Medical Center
Daniel Fabbri
Vanderbilt University Medical Center
Deborah Schrag
Memorial Sloan Kettering Cancer Center
Travis J. Osterman
Vanderbilt University Medical Center
Philippe L. Bedard
University Health Network
Matthew D. Hellmann
Weill Cornell Medical College
Make your next move.
Prepare your application
Review drafts before you send them.